Primatene Mist TV Ads Coming To Boost OTC Emergency Asthma Inhaler's Sales
"We will begin TV advertising campaign in July, which we think will really increase awareness of the product and hopefully give a good return on investment on those commercials," says Amphastar president Jason Shandell. Returning recently relaunched product to Walmart,later in 2019 "should be a big boost for us because that was over 35% of sales previously," says CFO William Peters.
You may also be interested in...
Glaxo plans to make changes FDA requested in Complete Response letter sent on 18 October, the agency’s deadline for acting on NDA for an oral spray that delivers 1 mg per spray of aqueous buffered nicotine solution for oromucosal use.
Examples of unfinished business from 2019 include no legislation passed to reform OTC monograph program; FDA putting off until May the planned publication of an NPRM to allow firms to submit OTC NDAs with extra-label information to help guide consumers' self-selection; and no OTC naloxone for opioid overdose approved even after FDA's unprecedented step of developing model DFLs sponsors could use for their own label comprehension studies.
Amphastar has initial inventory on hand of epinephrine inhalation aerosol reformulated with hydrofluoroalkane as a propellant, and expects "almost no costs" for sales of first several hundred thousand units. After two NDAs and two CRLs, firm convinces US FDA consumers can use the product without doctor or pharmacist guidance and understand it is not for ongoing asthma treatment.